期刊文献+

P^(53)和C-erbB-2在乳腺癌中的表达及意义 被引量:1

Expression of P^(53) and C-erbB-2 in Primary Breast Carcinoma and Its Clinical Significance
暂未订购
导出
摘要 目的分析研究P53和C-erbB-2在乳腺癌中的表达与转移及预后的关系。方法免疫组化法测定93例原发性乳腺癌中P53和C-erbB-2表达情况。结果P53和C-erbB-2在乳腺癌中阳性表达率分别为55.9%(52/93)和40.9%(38/93),其阳性表达率随着临床分期增加和腋窝淋巴结转移数目的增加而增加,差异有显著性(P<0.05);P53和C-erbB-2共同阳性表达与淋巴结转移差异有显著性(P<0.05)。结论P53、C-erbB-2是判断乳腺癌预后的有效指标,联合检测P53和C-erbB-2可指导临床综合治疗。 Objective To investigate the expression of P^53 and C- erbB- 2 and the relation to metastasis and prognosis of primary breast carcinoma. Methods The expression of P^53 and C- erbB - 2 were detected by immunochemical S- P methods in 95 cases of primary breast carcinoma. Results The expression rate of P^53 and C- erbB- 2 were 55.9 % (52/93) and 40, 9%(38/93) respectively, The positive rate of P^53 and C- erbB-2 increased with the number of metastasis lymph node and clinical stage, and there was a significant difference( P 〈 0.05). The Co-expression of P^53 and C-erbB- 2 related to lymph node metastasis significantly (P〈0.05). Conclusions P^53 and C - erbB - 2 are useful prognostic factors in patients with breast carcinoma. The combined detection of P^53 and C- erbB - 2 has important significance for clinical therapy.
出处 《实用全科医学》 2005年第6期489-490,共2页 Applied Journal Of General Practice
关键词 P^53 C-ERBB-2 乳腺癌 基因表达 免疫组织化学 肿瘤转移 Breast neoplasms P^53 gene C - erbB - 2 gene Lymphatic metastasis Irnrnunohistochemistry
  • 相关文献

参考文献3

二级参考文献11

共引文献26

同被引文献13

  • 1曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
  • 2曾瑄,梁智勇,武莎斐,周炜洵,高洁,刘彤华.乳腺癌HER2蛋白表达阳性者的基因状态分析[J].中华病理学杂志,2006,35(10):584-588. 被引量:40
  • 3Press MF, Slamon DJ, Flcm K J, et al. Evaluation of HER2/neu gene amplification and overexpression [ J ]. J Clin Oncol, 2002,20 : 3095- 3105.
  • 4Ross JS,Gray GS. Targeted therapy for cancer, the HER2/neu and Herceptin story[ J ]. Clin Leadersh Manag Rev,2003,17:333-340.
  • 5Vogel C, Cobleigh MA, Tripathy D, et al. First-line, single-agent Herceptin(R) (trastuzumab) in metastic breast cancer, a preliminary report[J]. Eur J Cancer,2001,37 Supp 11:25-29.
  • 6Lan C, Liu JM, Liu TW, et al. ErbB2 amplification by fluorescence in situ hybridization in breast cancer specimens read as + + in immunohistochemical analysis [ J ]. AM J Clin Pathol,2005,124 ( 1 ) :97-102.
  • 7Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER2 status inroutine practice [ J ]. Am J Clin Pathol,2005,123 ( 5 ) :766-770.
  • 8Fattanch A,Tavassoli, Peter Devilee. Pathology and Genetics, Tumours of the breast and Female Genital Organs[ M]. World Health Organization Classification of Tumours,北京:人民卫生出版社:2006:61.
  • 9Shak S. Overview of the trastuzumab ( Herceptin ) anti-HER2 monocolon antibody clinical program in HER-overexpressing metastatic breast cancer. Hereeptin Multinational Investigator Study Group [ J ]. Semin Oncol,1999,26(4 Suppl 12):71-77.
  • 10Hicks DG,Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization:a technical review with interpretive guidelines[ J]. Hum Pathol,2005,36:250-261.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部